Irritable Bowel Syndrome – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Irritable Bowel Syndrome – Pipeline Review, H2 2017’, provides an overview of the Irritable Bowel Syndrome pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Irritable Bowel Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Irritable Bowel Syndrome and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Irritable Bowel Syndrome

The report reviews pipeline therapeutics for Irritable Bowel Syndrome by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Irritable Bowel Syndrome therapeutics and enlists all their major and minor projects

The report assesses Irritable Bowel Syndrome therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Irritable Bowel Syndrome

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Irritable Bowel Syndrome

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Irritable Bowel Syndrome pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

4D Pharma PLC

Alfa Wassermann SpA

Allergan Plc

Aptevo Therapeutics Inc

Ardelyx Inc

Astellas Pharma Inc

ConSynance Therapeutics Inc

Cosmo Pharmaceuticals NV

Dong-A ST Co Ltd

Eisai Co Ltd

Enterome Bioscience SA

GlaxoSmithKline Plc

ImmuneBiotech AB

Innovative Med Concepts LLC

Ironwood Pharmaceuticals Inc

Kissei Pharmaceutical Co Ltd

Napo Pharmaceuticals Inc

Pfizer Inc

RaQualia Pharma Inc

RedHill Biopharma Ltd

Scythian Biosciences Corp

SK Biopharmaceuticals Co Ltd

Sumitomo Dainippon Pharma Co Ltd

Synergy Pharmaceuticals Inc

Synthetic Biologics Inc

Vitality Biopharma Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 8

Introduction 9

Global Markets Direct Report Coverage 9

Irritable Bowel Syndrome - Overview 10

Irritable Bowel Syndrome - Therapeutics Development 11

Pipeline Overview 11

Pipeline by Companies 12

Pipeline by Universities/Institutes 15

Products under Development by Companies 16

Products under Development by Universities/Institutes 19

Irritable Bowel Syndrome - Therapeutics Assessment 20

Assessment by Target 20

Assessment by Mechanism of Action 23

Assessment by Route of Administration 26

Assessment by Molecule Type 28

Irritable Bowel Syndrome - Companies Involved in Therapeutics Development 30

4D Pharma PLC 30

Alfa Wassermann SpA 30

Allergan Plc 30

Aptevo Therapeutics Inc 31

Ardelyx Inc 31

Astellas Pharma Inc 32

ConSynance Therapeutics Inc 32

Cosmo Pharmaceuticals NV 33

Dong-A ST Co Ltd 33

Eisai Co Ltd 34

Enterome Bioscience SA 34

GlaxoSmithKline Plc 34

ImmuneBiotech AB 35

Innovative Med Concepts LLC 35

Ironwood Pharmaceuticals Inc 36

Kissei Pharmaceutical Co Ltd 36

Napo Pharmaceuticals Inc 37

Pfizer Inc 37

RaQualia Pharma Inc 37

RedHill Biopharma Ltd 38

Scythian Biosciences Corp 38

SK Biopharmaceuticals Co Ltd 39

Sumitomo Dainippon Pharma Co Ltd 39

Synergy Pharmaceuticals Inc 40

Synthetic Biologics Inc 40

Vitality Biopharma Inc 40

Irritable Bowel Syndrome - Drug Profiles 42

(celecoxib + famciclovir) - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

APVO-210 - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

ASP-7147 - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

bedoradrine sulfate - Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

Biologic for Irritable Bowel Syndrome with Constipation - Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

Biologic for Irritable Bowel Syndrome with Diarrhea - Drug Profile 51

Product Description 51

Mechanism Of Action 51

R&D Progress 51

Blautix - Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

Canchew Plus - Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

crofelemer DR - Drug Profile 55

Product Description 55

Mechanism Of Action 55

R&D Progress 55

CSTI-300 - Drug Profile 59

Product Description 59

Mechanism Of Action 59

R&D Progress 59

DA-6886 - Drug Profile 60

Product Description 60

Mechanism Of Action 60

R&D Progress 60

Drugs for Irritable Bowel Syndrome with Diarrhea - Drug Profile 61

Product Description 61

Mechanism Of Action 61

R&D Progress 61

DSP-6952 - Drug Profile 62

Product Description 62

Mechanism Of Action 62

R&D Progress 62

E-2508 - Drug Profile 63

Product Description 63

Mechanism Of Action 63

R&D Progress 63

EB-410 - Drug Profile 64

Product Description 64

Mechanism Of Action 64

R&D Progress 64

EB-420 - Drug Profile 65

Product Description 65

Mechanism Of Action 65

R&D Progress 65

GSK-3179106 - Drug Profile 66

Product Description 66

Mechanism Of Action 66

R&D Progress 66

IB-001 - Drug Profile 67

Product Description 67

Mechanism Of Action 67

R&D Progress 67

linaclotide - Drug Profile 68

Product Description 68

Mechanism Of Action 68

R&D Progress 68

linaclotide DR1 - Drug Profile 76

Product Description 76

Mechanism Of Action 76

R&D Progress 76

linaclotide DR2 - Drug Profile 77

Product Description 77

Mechanism Of Action 77

R&D Progress 77

lovastatin MR - Drug Profile 78

Product Description 78

Mechanism Of Action 78

R&D Progress 78

LT-4006 - Drug Profile 82

Product Description 82

Mechanism Of Action 82

R&D Progress 82

Lyrica - Drug Profile 83

Product Description 83

Mechanism Of Action 83

R&D Progress 83

ondansetron hydrochloride CR - Drug Profile 88

Product Description 88

Mechanism Of Action 88

R&D Progress 88

ORP-101 - Drug Profile 96

Product Description 96

Mechanism Of Action 96

R&D Progress 96

PBF-677 - Drug Profile 97

Product Description 97

Mechanism Of Action 97

R&D Progress 97

plecanatide - Drug Profile 98

Product Description 98

Mechanism Of Action 98

R&D Progress 98

PR-38 - Drug Profile 107

Product Description 107

Mechanism Of Action 107

R&D Progress 107

RDX-023 - Drug Profile 108

Product Description 108

Mechanism Of Action 108

R&D Progress 108

relenopride hydrochloride - Drug Profile 109

Product Description 109

Mechanism Of Action 109

R&D Progress 109

rifamycin CR - Drug Profile 111

Product Description 111

Mechanism Of Action 111

R&D Progress 111

rifaximin - Drug Profile 114

Product Description 114

Mechanism Of Action 114

R&D Progress 114

RQ-00202730 - Drug Profile 119

Product Description 119

Mechanism Of Action 119

R&D Progress 119

RQ-00310941 - Drug Profile 120

Product Description 120

Mechanism Of Action 120

R&D Progress 120

SCY-002P - Drug Profile 121

Product Description 121

Mechanism Of Action 121

R&D Progress 121

Small Molecules to Inhibit 5-HT2B and 5-HT7 Receptors for IBS and Migraine - Drug Profile 122

Product Description 122

Mechanism Of Action 122

R&D Progress 122

solabegron hydrochloride - Drug Profile 123

Product Description 123

Mechanism Of Action 123

R&D Progress 123

tenapanor - Drug Profile 126

Product Description 126

Mechanism Of Action 126

R&D Progress 126

VB-210 - Drug Profile 132

Product Description 132

Mechanism Of Action 132

R&D Progress 132

Irritable Bowel Syndrome - Dormant Projects 133

Irritable Bowel Syndrome - Discontinued Products 136

Irritable Bowel Syndrome - Product Development Milestones 137

Featured News & Press Releases 137

Oct 19, 2017: Jaguar Health Subsidiary Napo Pharmaceuticals Establishes Scientific Advisory Boards for Planned Follow-on Indications for Mytesi, Napo’s FDA-approved Human Prescription Drug 137

Oct 16, 2017: Aptevo Therapeutics Showcases New Mechanism of Action for Its ADAPTIR Platform at the Inflammation Research Society Meeting 138

Oct 16, 2017: Allergan to Present New Data on Gastrointestinal Drug Candidate Linaclotide at the World Congress of Gastroenterology at ACG 2017 140

Oct 16, 2017: Ardelyx Announces Tenapanor Reduces Pain Caused by IBS-C Through Inhibition of TRPV-1 Signaling 140

Oct 12, 2017: Synergy Pharmaceuticals to Highlight New Data for TRULANCE (Plecanatide) at the World Congress of Gastroenterology at American College of Gastroenterology 141

Oct 11, 2017: Ardelyxs Pivotal Phase 3 Study of Tenapanor for IBS-C Hits Primary and All Secondary Endpoints to Support NDA Submission in 2018 141

Oct 03, 2017: RedHill Biopharma Announces Positive Top-Line Results from Phase II Study of BEKINDA in Patients with IBS-D 143

Sep 28, 2017: RedHill Biopharma to Announce Top-Line Results from BEKINDA 12 mg Phase II Study for IBS-D on October 3rd, 2017 145

Jul 17, 2017: RedHill Biopharma Announces Last Patient Visit in BEKINDA Phase II Study for IBS-D 145

Jun 27, 2017: Synthetic Biologics Announces Allowance of Key U.S. Patent Covering SYN-010 Intended for the Novel Treatment of Irritable Bowel Syndrome with Constipation 146

Jun 07, 2017: Synergy Pharmaceuticals Announces Acceptance of Supplemental New Drug Application (sNDA) for TRULANCE (Plecanatide) for the Treatment of Adults with Irritable Bowel Syndrome with Constipation 147

May 12, 2017: Ardelyx Reports Successful Phase 3 T3MPO-1 Trial of Tenapanor in Patients with IBS-C 147

May 09, 2017: Ironwood Pharmaceuticals Presents Data Further Elucidating Linaclotide's Effect on Pain at Digestive Disease Week 2017 149

May 01, 2017: Allergan to Present Linzess and Linaclotide Delayed Release Data at Digestive Disease Week 2017 151

May 01, 2017: Synergy Pharmaceuticals to Highlight New Data for TRULANCE (Plecanatide) at Digestive Disease Week 152

Appendix 153

Methodology 153

Coverage 153

Secondary Research 153

Primary Research 153

Expert Panel Validation 153

Contact Us 153

Disclaimer 154

List of Tables

List of Tables

Number of Products under Development for Irritable Bowel Syndrome, H2 2017 11

Number of Products under Development by Companies, H2 2017 13

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017 14

Number of Products under Development by Universities/Institutes, H2 2017 15

Products under Development by Companies, H2 2017 16

Products under Development by Companies, H2 2017 (Contd..1), H2 2017 17

Products under Development by Companies, H2 2017 (Contd..2), H2 2017 18

Products under Development by Universities/Institutes, H2 2017 19

Number of Products by Stage and Target, H2 2017 21

Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017 22

Number of Products by Stage and Mechanism of Action, H2 2017 24

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017 25

Number of Products by Stage and Route of Administration, H2 2017 27

Number of Products by Stage and Molecule Type, H2 2017 29

Irritable Bowel Syndrome – Pipeline by 4D Pharma PLC, H2 2017 30

Irritable Bowel Syndrome – Pipeline by Alfa Wassermann SpA, H2 2017 30

Irritable Bowel Syndrome – Pipeline by Allergan Plc, H2 2017 31

Irritable Bowel Syndrome – Pipeline by Aptevo Therapeutics Inc, H2 2017 31

Irritable Bowel Syndrome – Pipeline by Ardelyx Inc, H2 2017 32

Irritable Bowel Syndrome – Pipeline by Astellas Pharma Inc, H2 2017 32

Irritable Bowel Syndrome – Pipeline by ConSynance Therapeutics Inc, H2 2017 33

Irritable Bowel Syndrome – Pipeline by Cosmo Pharmaceuticals NV, H2 2017 33

Irritable Bowel Syndrome – Pipeline by Dong-A ST Co Ltd, H2 2017 33

Irritable Bowel Syndrome – Pipeline by Eisai Co Ltd, H2 2017 34

Irritable Bowel Syndrome – Pipeline by Enterome Bioscience SA, H2 2017 34

Irritable Bowel Syndrome – Pipeline by GlaxoSmithKline Plc, H2 2017 35

Irritable Bowel Syndrome – Pipeline by ImmuneBiotech AB, H2 2017 35

Irritable Bowel Syndrome – Pipeline by Innovative Med Concepts LLC, H2 2017 35

Irritable Bowel Syndrome – Pipeline by Ironwood Pharmaceuticals Inc, H2 2017 36

Irritable Bowel Syndrome – Pipeline by Kissei Pharmaceutical Co Ltd, H2 2017 36

Irritable Bowel Syndrome – Pipeline by Napo Pharmaceuticals Inc, H2 2017 37

Irritable Bowel Syndrome – Pipeline by Pfizer Inc, H2 2017 37

Irritable Bowel Syndrome – Pipeline by RaQualia Pharma Inc, H2 2017 38

Irritable Bowel Syndrome – Pipeline by RedHill Biopharma Ltd, H2 2017 38

Irritable Bowel Syndrome – Pipeline by Scythian Biosciences Corp, H2 2017 39

Irritable Bowel Syndrome – Pipeline by SK Biopharmaceuticals Co Ltd, H2 2017 39

Irritable Bowel Syndrome – Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2 2017 39

Irritable Bowel Syndrome – Pipeline by Synergy Pharmaceuticals Inc, H2 2017 40

Irritable Bowel Syndrome – Pipeline by Synthetic Biologics Inc, H2 2017 40

Irritable Bowel Syndrome – Pipeline by Vitality Biopharma Inc, H2 2017 41

Irritable Bowel Syndrome – Dormant Projects, H2 2017 133

Irritable Bowel Syndrome – Dormant Projects, H2 2017 (Contd..1), H2 2017 134

Irritable Bowel Syndrome – Dormant Projects, H2 2017 (Contd..2), H2 2017 135

Irritable Bowel Syndrome – Discontinued Products, H2 2017 136

List of Figures

List of Figures

Number of Products under Development for Irritable Bowel Syndrome, H2 2017 11

Number of Products under Development by Companies, H2 2017 12

Number of Products by Targets, H2 2017 20

Number of Products by Stage and Top 10 Targets, H2 2017 20

Number of Products by Top 10 Mechanism of Actions, H2 2017 23

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017 23

Number of Products by Routes of Administration, H2 2017 26

Number of Products by Stage and Routes of Administration, H2 2017 26

Number of Products by Molecule Types, H2 2017 28

Number of Products by Stage and Top 10 Molecule Types, H2 2017 28

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports